<DOC>
	<DOCNO>NCT01502293</DOCNO>
	<brief_summary>This study ass safety effectiveness intratumoral plasmid interleukin-12 DNA injection ( pIL-12 ) electroporation ( EP ) malignant melanoma . Intratumoral pIL-12 EP gene therapy approach directly induce pro-inflammatory response within tumor initiate and/or enhance anti-tumor immunity .</brief_summary>
	<brief_title>Trial pIL-12 Electroporation Malignant Melanoma</brief_title>
	<detailed_description>Plasmid IL-12 ( pIL-12 ) concentration 0.5 mg/mL inject intratumorally dose volume ¼ calculate lesion volume dose volume per lesion 0.1 mL lesion volume &lt; 0.4 cm3 . Six pulse field strength ( E+ ) 1500 V/cm pulse width 100 μs 1-second interval administer use OMS previously inject tumor . Two treatment regimen explore : Regimen A : Treatment Days 1 , 8 15 every 6 week Regimen B : Treatment Days 1 , 5 8 every 6 week . Lesions treat either Regimen A Regimen B . Subsequent cycle may give 6-week interval , 9 treatment cycle total .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Patients advance cutaneous subcutaneous intransit metastatic melanoma Age ≥ 18 year age ECOG performance status 02 Patients may prior chemotherapy immunotherapy ( vaccine , interferon , ipilimumab , IL2 ) progression persistent disease Patients may radiation therapy , must progressive disease radiation therapy lesion treat within radiation field Female patient childbearing potential negative pregnancy test within 14 day prior start study drug Adequate organ function Able give inform consent Prior therapy IL12 prior gene therapy Concurrent immunotherapy , chemotherapy , radiation therapy duration subject participation study Evidence significant active infection ( e.g. , pneumonia , cellulitis , wound abscess , etc . ) time study enrollment Pregnant breastfeed woman Patients electronic pacemaker defibrillator exclude study The patient know positive Human Immunodeficiency Virus ( HIV ) another confirm suspect immunosuppressive immunodeficient condition ( patient thyroiditis eligible ) Life expectancy le 6 month History significant cardiovascular disease ( i.e . NYHA class 3 congestive heart failure ; myocardial infarction past 6 month ; unstable angina ; coronary angioplasty past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia ) Other clinically significant comorbidities uncontrolled pulmonary disease , uncontrolled diabetes , active CNS disease , active infection condition could compromise patient participation study accord investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>